John Renger - Dec 21, 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 21, 2021
Transactions value $
-$211,700
Form type
4
Date filed
12/23/2021, 04:14 PM
Previous filing
Dec 17, 2021
Next filing
Dec 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $25.6K +7.3K +368.69% $3.50* 9.28K Dec 21, 2021 Direct F1, F2
transaction CERE Common Stock Sale -$237K -7.3K -78.66% $32.50 1.98K Dec 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -7.3K -1.88% $0.00 381K Dec 21, 2021 Common Stock 7.3K $3.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021.
F3 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.